TABLE 4.
Neonatal Antiretroviral (ARV) Drug Dosing for Prevention of Mother-to-Child Transmission of HIV
| ARV Drug | Dosing | Duration |
|---|---|---|
| Zidovudine (ZDV) should be given to ALL HIV-exposed newborns and should be started as soon after birth as possible, preferably within 6–12 hours of delivery | ||
| ZDV | ≥35 weeks’ gestation at birth: 4 mg/kg/dose PO twice daily (if unable to tolerate oral agents, 3 mg/kg/dose IV, beginning within 6–12 hours of delivery, then every 12 hours) | Birth through 6 weeks |
| ZDV | ≥30 to <35 weeks’ gestation at birth: 2 mg/kg/dose PO (or 1.5 mg/kg/dose IV) every 12 hours, advanced to 3 mg/kg/dose PO (or 2.3 mg/kg/dose IV) every 12 hours at age 15 days | Birth through 6 weeks |
| ZDV | <30 weeks’ gestation at birth: 2 mg/kg body weight/dose PO (or 1.5 mg/kg/dose IV) every 12 hours, advanced to 3 mg/kg/dose PO (or 2.3 mg/kg/dose IV) every 12 hours after age 4 weeks | Birth through 6 weeks |
| Nevirapine (NVP) administered in addition to ZDV to Newborns of HIV-infected Women who Received No Antepartum ARV Prophylaxis | ||
| Nevirapine (NVP) |
Weight Band dosing Birth weight 1.5–2 kg: 8 mg* for each dose Birth weight >2 kg: 12 mg* for each dose (*NOTE: NVP dosing given as actual doses, NOT as mg/kg dosing) |
3 doses in the first week of life
|